Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

REVIVE THERAPEUTICS CSE : RVV | OTC : RVVTF TORONTO, Nov. 18, 2020 (GLOBE NEWSWIRE) —…

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Revive Therapeutics Ltd. RVV | RVVTF TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd.…

This company in phase 3 (FDA) for a Covid-19 treatment can no longer be ignored by investors | RVV RVVTF

Since the start of the Covid 19 pandemic, all the experts on the planet have been…

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Oct. 26, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

TORONTO, Oct. 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics finalizes five clinical sites for their FDA COVID-19 Phase 3

Revive Therapeutics | CSE: RVV USA: RVVTF Today, Revive Therapeutics issued an important press release to…

A centerpiece in the psychedelics market : Revive Therapeutics

Last week, the booming psychedelic market saw the first psychedelic company to surpass $1 billion in…

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

TORONTO, Sept. 16, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

A penny stock to watch closely in the treatment of covid-19

For months, while the whole world has been looking for a solution for the Covid-19 pandemic,…